EA200970838A1 - ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛИРОВАННЫЕ ТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α - Google Patents
ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛИРОВАННЫЕ ТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ αInfo
- Publication number
- EA200970838A1 EA200970838A1 EA200970838A EA200970838A EA200970838A1 EA 200970838 A1 EA200970838 A1 EA 200970838A1 EA 200970838 A EA200970838 A EA 200970838A EA 200970838 A EA200970838 A EA 200970838A EA 200970838 A1 EA200970838 A1 EA 200970838A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- arthritis
- disease
- cartilage
- chronic
- disorders
- Prior art date
Links
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 210000000845 cartilage Anatomy 0.000 abstract 3
- 206010003246 arthritis Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89345807P | 2007-03-07 | 2007-03-07 | |
| PCT/US2008/056018 WO2008109731A2 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200970838A1 true EA200970838A1 (ru) | 2010-02-26 |
Family
ID=39720674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200970838A EA200970838A1 (ru) | 2007-03-07 | 2008-03-06 | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛИРОВАННЫЕ ТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8119669B2 (https=) |
| EP (1) | EP2132188B1 (https=) |
| JP (1) | JP2010520307A (https=) |
| KR (1) | KR20090118103A (https=) |
| CN (1) | CN101679326B (https=) |
| AR (1) | AR065656A1 (https=) |
| AT (1) | ATE537157T1 (https=) |
| AU (1) | AU2008222749A1 (https=) |
| BR (1) | BRPI0808662B8 (https=) |
| CA (1) | CA2679965A1 (https=) |
| CL (1) | CL2008000669A1 (https=) |
| CY (1) | CY1112778T1 (https=) |
| DK (1) | DK2132188T3 (https=) |
| EA (1) | EA200970838A1 (https=) |
| ES (1) | ES2377165T3 (https=) |
| HR (1) | HRP20120160T1 (https=) |
| IL (1) | IL200758A0 (https=) |
| MX (1) | MX2009009519A (https=) |
| NZ (1) | NZ579418A (https=) |
| PL (1) | PL2132188T3 (https=) |
| PT (1) | PT2132188E (https=) |
| RS (1) | RS52247B (https=) |
| SI (1) | SI2132188T1 (https=) |
| TW (1) | TW200902507A (https=) |
| WO (1) | WO2008109731A2 (https=) |
| ZA (1) | ZA200906953B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200902508A (en) * | 2007-03-07 | 2009-01-16 | Janssen Pharmaceutica Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators |
| US8252937B2 (en) | 2007-09-14 | 2012-08-28 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
| PL2203439T3 (pl) | 2007-09-14 | 2011-06-30 | Addex Pharmaceuticals Sa | 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony |
| US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| RU2492170C9 (ru) | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2 |
| US7973062B2 (en) * | 2008-02-22 | 2011-07-05 | The Ohio State University Research Foundation | Androgen receptor-ablative agents |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153912A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| JP2011057643A (ja) * | 2009-09-14 | 2011-03-24 | Sumitomo Chemical Co Ltd | ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物 |
| JP2011057644A (ja) * | 2009-09-14 | 2011-03-24 | Sumitomo Chemical Co Ltd | ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物 |
| JP2013519730A (ja) * | 2010-02-17 | 2013-05-30 | ヤンセン ファーマシューティカ エヌ．ベー． | エストロゲン関連受容体α変調剤としてのアミノチアゾロン |
| CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JP6014816B2 (ja) * | 2011-05-10 | 2016-10-26 | 国立大学法人神戸大学 | Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体 |
| US8772277B2 (en) | 2011-08-04 | 2014-07-08 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| CA2868311C (en) | 2012-03-26 | 2021-06-22 | Nippon Chemiphar Co., Ltd. | Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma |
| US20160169896A1 (en) * | 2012-10-17 | 2016-06-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for Predicting and Treating Bone Metastases in Prostate Cancer Patients |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EP3050573B1 (en) | 2013-09-25 | 2019-12-11 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma |
| KR20220049612A (ko) | 2014-01-21 | 2022-04-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| HUE053734T2 (hu) | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| EP4316477A1 (en) | 2018-08-22 | 2024-02-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods for treating cardiac valve disease |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) * | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JP2001072592A (ja) * | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| EP1109796A1 (en) * | 1999-07-01 | 2001-06-27 | Geron Corporation | Telomerase inhibitors and methods of their use |
| AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| DE10131899A1 (de) | 2001-07-04 | 2003-02-27 | Boehringer Ingelheim Pharma | In vitro-Screening-Assay für gamma-Secretase |
| JP2006500399A (ja) * | 2002-04-30 | 2006-01-05 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| WO2006004555A1 (en) | 2004-06-30 | 2006-01-12 | Paysetter Pte Ltd | System and method for facilitating transfer of physical money and/or credit |
| US20060014812A1 (en) * | 2004-07-14 | 2006-01-19 | Player Mark R | Use of estrogen related receptor-modulating aryl ethers |
| JP4931824B2 (ja) | 2004-10-22 | 2012-05-16 | エグゼリクシス， インコーポレイテッド | 薬学的組成物 |
-
2008
- 2008-03-06 AT AT08731517T patent/ATE537157T1/de active
- 2008-03-06 SI SI200830561T patent/SI2132188T1/sl unknown
- 2008-03-06 ES ES08731517T patent/ES2377165T3/es active Active
- 2008-03-06 MX MX2009009519A patent/MX2009009519A/es active IP Right Grant
- 2008-03-06 EA EA200970838A patent/EA200970838A1/ru unknown
- 2008-03-06 TW TW097107936A patent/TW200902507A/zh unknown
- 2008-03-06 BR BRPI0808662A patent/BRPI0808662B8/pt not_active IP Right Cessation
- 2008-03-06 RS RS20120106A patent/RS52247B/sr unknown
- 2008-03-06 HR HR20120160T patent/HRP20120160T1/hr unknown
- 2008-03-06 AU AU2008222749A patent/AU2008222749A1/en not_active Abandoned
- 2008-03-06 PL PL08731517T patent/PL2132188T3/pl unknown
- 2008-03-06 PT PT08731517T patent/PT2132188E/pt unknown
- 2008-03-06 JP JP2009552883A patent/JP2010520307A/ja active Pending
- 2008-03-06 US US12/043,291 patent/US8119669B2/en not_active Expired - Fee Related
- 2008-03-06 WO PCT/US2008/056018 patent/WO2008109731A2/en not_active Ceased
- 2008-03-06 EP EP08731517A patent/EP2132188B1/en active Active
- 2008-03-06 KR KR1020097020832A patent/KR20090118103A/ko not_active Withdrawn
- 2008-03-06 CA CA002679965A patent/CA2679965A1/en not_active Abandoned
- 2008-03-06 NZ NZ579418A patent/NZ579418A/en not_active IP Right Cessation
- 2008-03-06 CL CL2008000669A patent/CL2008000669A1/es unknown
- 2008-03-06 DK DK08731517.2T patent/DK2132188T3/da active
- 2008-03-06 CN CN2008800153616A patent/CN101679326B/zh not_active Expired - Fee Related
- 2008-03-07 AR ARP080100963A patent/AR065656A1/es not_active Application Discontinuation
-
2009
- 2009-09-06 IL IL200758A patent/IL200758A0/en unknown
- 2009-10-06 ZA ZA2009/06953A patent/ZA200906953B/en unknown
-
2012
- 2012-01-10 US US13/346,808 patent/US9034852B2/en not_active Expired - Fee Related
- 2012-03-07 CY CY20121100232T patent/CY1112778T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9034852B2 (en) | 2015-05-19 |
| EP2132188A2 (en) | 2009-12-16 |
| US20120108571A1 (en) | 2012-05-03 |
| ATE537157T1 (de) | 2011-12-15 |
| BRPI0808662A2 (pt) | 2014-08-26 |
| RS52247B (sr) | 2012-10-31 |
| TW200902507A (en) | 2009-01-16 |
| BRPI0808662B1 (pt) | 2020-09-29 |
| ES2377165T3 (es) | 2012-03-23 |
| DK2132188T3 (da) | 2012-02-27 |
| KR20090118103A (ko) | 2009-11-17 |
| BRPI0808662B8 (pt) | 2021-05-25 |
| CA2679965A1 (en) | 2008-09-12 |
| CN101679326B (zh) | 2012-12-12 |
| CY1112778T1 (el) | 2016-02-10 |
| MX2009009519A (es) | 2009-11-18 |
| PL2132188T3 (pl) | 2012-05-31 |
| WO2008109731A3 (en) | 2008-11-27 |
| EP2132188B1 (en) | 2011-12-14 |
| AR065656A1 (es) | 2009-06-24 |
| HRP20120160T1 (hr) | 2012-03-31 |
| SI2132188T1 (sl) | 2012-04-30 |
| US8119669B2 (en) | 2012-02-21 |
| JP2010520307A (ja) | 2010-06-10 |
| US20080286265A1 (en) | 2008-11-20 |
| ZA200906953B (en) | 2010-12-29 |
| NZ579418A (en) | 2012-01-12 |
| IL200758A0 (en) | 2010-05-17 |
| AU2008222749A1 (en) | 2008-09-12 |
| CL2008000669A1 (es) | 2008-11-03 |
| PT2132188E (pt) | 2012-02-13 |
| WO2008109731A2 (en) | 2008-09-12 |
| CN101679326A (zh) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200970838A1 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛИРОВАННЫЕ ТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α | |
| EA200970837A1 (ru) | ЗАМЕЩЁННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ α-РЕЦЕПТОРА ЭСТРОГЕНА | |
| EA200970839A1 (ru) | ЗАМЕЩЁННЫЕ ФЕНОКСИ АМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α | |
| TW201144303A (en) | Aminothiazolones as estrogen related receptor-α modulators | |
| MX2012009528A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| JP2010520308A5 (https=) | ||
| CY1114804T1 (el) | Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις | |
| CY1108752T1 (el) | Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα | |
| JP2010520307A5 (https=) | ||
| CY1117038T1 (el) | Υποκατεστημενες εναμινοκαρβονυλ ενωσεις | |
| WO2010059239A3 (en) | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders | |
| ECSP088414A (es) | Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria | |
| RU2008110697A (ru) | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) | |
| JP2018506543A5 (https=) | ||
| EP2131092A4 (en) | SEAMLESS ARC TUBE, WELD CONNECTION TO THE SEAMLESS ARC TUBE AND METHOD FOR THE PRODUCTION THEREOF | |
| JP2012054542A5 (ja) | トリアゾール誘導体および複素環化合物 | |
| NO20083406L (no) | FGF-reseptorer for dimere forbindelser | |
| EA201190207A1 (ru) | Соединения для лечения метаболических расстройств | |
| JP2020510119A5 (https=) | ||
| JP2012131782A5 (https=) | ||
| UA97975C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α | |
| WO2007102446A3 (en) | Method and composition for treating chronic obstructive pulmonary disease | |
| JP2009242532A5 (https=) | ||
| JP2018500324A5 (https=) | ||
| JP2017507188A5 (https=) |